Marker Therapeutics, Inc.
Marker Therapeutics, Inc. (MRKR) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MRKR · as of Jun 8, 2026
Key Statistics
Explore Marker Therapeutics, Inc. Data
mrkr stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 60.0%
Competitors & Peers
mrkr competitorsMRKR
AEON
BOLT
CLRB
COCP
EVGNStock Performance
Full HistoryAbout Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-…
what is marker therapeutics, inc. · mrkr stock overview · marker therapeutics, inc. company profile · who is marker therapeutics, inc. ceo · mrkr NASDAQ · marker therapeutics, inc. headquarters · marker therapeutics, inc. business segments
About Stock Overview & Key Data
Marker Therapeutics, Inc. (MRKR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 16, 2002. As of the latest trading session, MRKR stock price is $1.46, with a market capitalization of $15.8M. The stock has returned -15.12% over the past 12 months and -2.01% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Marker Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Marker Therapeutics, Inc. reported revenue of — and net income of -$12.2M. For detailed data — including Marker Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Marker Therapeutics, Inc. (MRKR) stock price is $1.46. The stock is traded on NASDAQ under the ticker symbol MRKR. The 52-week range is $0.81 – $4.07.